GT BIOPHARMA, INC. Dividends, Preferred Stock, Stock
GT BIOPHARMA, INC. (GTBP) reported Dividends, Preferred Stock, Stock of $74.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Dividends, Preferred Stock
us-gaap:DividendsPreferredStockStock · last filed 2026-08-14
- GT BIOPHARMA, INC. dividends, preferred stock, stock for the quarter ending 2026-06-30 was $74.00K, a 12.94% decline year-over-year.
- GT BIOPHARMA, INC. dividends, preferred stock, stock for the quarter ending 2026-03-31 was $103.00K.
- GT BIOPHARMA, INC. dividends, preferred stock, stock for the quarter ending 2025-06-30 was $85.00K.
| Period end | Dividends, Preferred Stock, Stock 3 month | Dividends, Preferred Stock, Stock 6 month |
|---|---|---|
| 2026-06-30 | $74.00K 10-Q · filed 2026-08-14 | $177.00K 10-Q · filed 2026-08-14 |
| 2026-03-31 | $103.00K 10-Q · filed 2026-05-15 | |
| 2025-06-30 | $85.00K 10-Q · filed 2026-08-14 | $85.00K 10-Q · filed 2026-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |